A randomized, double-blind, active-controlled, phase I clinical study to evaluate the safety, tolerability, and immunogenicity of a COVID-19 mRNA vaccine (in002.5.1) in comparison with an approved mRNA booster vaccine for COVID-19 in population >= 18 years of age
100 Clinical Results associated with Shenzhen Shenxin Biotechnology Co., Ltd.
0 Patents (Medical) associated with Shenzhen Shenxin Biotechnology Co., Ltd.
100 Deals associated with Shenzhen Shenxin Biotechnology Co., Ltd.
100 Translational Medicine associated with Shenzhen Shenxin Biotechnology Co., Ltd.